Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Active Founders
Arne Scheu, Founder
Rhodes Scholar & DPhil Biochemistry from the University of Oxford
Irsyad Khairil, Founder
Pharma analyst with a background in protein engineering
DPhil in Biochemistry from the University of Oxford
